Age-related macular degeneration (AMD) associated with glucagon-like peptide-1 receptor agonist use: a systematic review.

“Age-related macular degeneration (AMD) associated with glucagon-like peptide-1 receptor agonist use: a systematic review. Al-Burak SA(1), Suleiman A(1), Voznyy V(2), Elganga M(2), Zajner C(3), Juncal V(4), Sheidow TG(4), Malvankar-Mehta MS(5). Author information: (1)Schulich School of Medicine & Dentistry, The University of Western Ontario, London ON. (2)Temerty Medicine, The University of Toronto, Toronto ON. (3)Ivey Eye Institute, St. Joseph's Health Care Centre, London ON. (4)Ivey Eye Institute, St. Joseph's Health Care Centre, London ON; Department of Ophthalmology and Visual Sciences, University of Western Ontario, London, ON. (5)Ivey Eye Institute, St. Joseph's Health Care Centre, London ON; Department of Ophthalmology and Visual Sciences, University of Western Ontario, London, ON; Department of Epidemiology and Biostatistics, University of Western Ontario, London ON. Electronic address: monali.malvankar@schulich.uwo.ca. BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for diabetes, obesity, and cardiovascular risk reduction. However, their ocular safety profile, particularly regarding age-related macular degeneration (AMD), remains uncertain. This systematic review evaluates the association between GLP-1 RA use and the incidence or progression of AMD including both nonexudative and neovascular subtypes. METHODS: A systematic review was conducted in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines and registered with PROSPERO (CRD420251183938). MEDLINE, Embase, CENTRAL, Web of Science, and PubMed were searched from inception through 2025 for observational studies and randomized trials evaluating AMD outcomes among adults exposed to GLP-1 RAs. Comparators included nonuse, placebo, or alternative metabolic therapies. Risk of bias was assessed using Risk of Bias in Non-Randomized Studies of Interventions and certainty of evidence using the Grading of Recommendations, Assessment, Development, and Evaluation framework. Due to heterogeneity of outcome definitions, results were synthesized qualitatively. RESULTS: Eight observational studies encompassing 91 408 to 600 816 participants were included. GLP-1 RA use was associated with a reduced incidence of nonexudative AMD across diabetic and nondiabetic populations, with relative risk reductions varying substantially by population, comparator, and follow-up duration. Findings for neovascular AMD were heterogeneous: most studies reported neutral or protective associations, whereas one population-based cohort of older adults with diabetes observed an increased risk (adjusted hazard ratio 2.21, 95% CI 1.65-2.96), with low absolute event rates. Overall risk of bias was moderate to high, and certainty of evidence for all outcomes was very low. CONCLUSIONS: Current evidence does not demonstrate a consistent increase in AMD risk associated with GLP-1 RA therapy and may be associated with a lower incidence of nonexudative AMD, although the certainty of evidence is very low and noncausal explanations cannot be excluded. Prospective studies with standardized endpoints are needed to clarify causal relationships. Copyright © 2026 The Authors. Published by Elsevier Inc. All rights reserved. Conflict of interest statement: Footnotes and Disclosures The authors have no proprietary or commercial interest in any materials discussed in this article.”